{"entity":{"id":"nct05929885","kind":"trial","name":"Metronomic Capecitabine, Oxaliplatin and UGT1A1 Genotype-directed Irinotecan in Metastatic Pancreatic Cancer Patients","aka":[],"tldr":"A phase 2 trial in pancreatic cancer, run by National Cancer Centre, Singapore, now recruiting.","summary":"Metronomic Capecitabine, Oxaliplatin and UGT1A1 Genotype-directed Irinotecan in Metastatic Pancreatic Cancer Patients is a phase 2, interventional study registered as NCT05929885 by National Cancer Centre, Singapore, with a registry enrolment figure of 50 participants, started 2023-08-30 and due to reach its primary completion in 2027-02-28. Interventions recorded: Low Dose OXIRI (LD-OXIRI). Conditions listed: Metastatic Pancreatic Cancer. Primary outcome: Overall Response Rate (ORR).; Clinical Benefit Rate (CBR).; The Grade 3-5 Toxicity Rate.. Pancreatic eligibility wording from the registry: \"Histopathological diagnosis of pancreatic cancer\". Sites: Singapore. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT05929885","url":"https://clinicaltrials.gov/study/NCT05929885"}],"tags":["ctgov-ingest","pancreatic-deep-dive"],"related":[],"cancers":["metastatic-pdac"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05929885","phase":"2","setting":"A Phase II Study of Metronomic Capecitabine, Oxaliplatin and UGT1A1 Genotype-directed Irinotecan in Metastatic Pancreatic Cancer Patients.","sponsor":"National Cancer Centre, Singapore","participation":[{"nct":"NCT05929885","source":"https://clinicaltrials.gov/study/NCT05929885","fetchedAt":"2026-10-07T16:54:02.117Z","studySha256":"e1c5e33e59926f8858471d05bee0bd4c318881aecc5dfc057ad18dde1b31585a","overallStatus":"RECRUITING","lastUpdatePosted":"2026-06-23","leadSponsor":"National Cancer Centre, Singapore","collaboratorCount":1,"minimumAge":"21 Years","maximumAge":"99 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":50,"enrolmentType":"ESTIMATED","siteCount":1,"recruitingSiteCount":1,"countries":["Singapore"]}],"started":"2023-08-30","startedType":"actual","enrolled":50,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05929885/","neighbours":{"cancer":[{"id":"metastatic-pdac","kind":"cancer","name":"Metastatic pancreatic ductal adenocarcinoma","route":"/cancers/metastatic-pdac/"}],"term":[{"id":"pancreatic-trials-open-today","kind":"term","name":"Pancreatic cancer trials open today (registry snapshot and UK sites)","route":"/terms/pancreatic-trials-open-today/"}]}}